FDA Finds Repeat Deficiencies at Ohio Outsourcer

Drug Industry Daily
A A
The FDA hit an Ohio outsourcing facility with an extensive Form 483, listing failures to adhere to GMP and overall sterility, cleaning and quality control issues—with several problems repeated from an inspection a year before.

To View This Article:

Login

Subscribe To Drug Industry Daily